Seres Therapeutics (MCRB)

Executive Summary

Seres Therapeutics is a pioneering microbiome company that achieved a historic milestone with the 2023 FDA approval of VOWST™ (SER-109), the first orally administered microbiome therapeutic for recurrent C. difficile infection. The company's proprietary platform enables the development of defined bacterial consortia to restore microbiome health and treat serious diseases. VOWST’s commercial launch is the primary near-term value driver, with growing prescription trends and expanding payer coverage. Beyond VOWST, Seres is advancing a pipeline focused on infectious and inflammatory diseases, leveraging its deep understanding of microbiome biology. The most advanced pipeline candidate is SER-155, a consortium designed to prevent bloodstream infections and graft-versus-host disease in allogeneic hematopoietic stem cell transplant recipients. Phase 1b results have been encouraging, and a Phase 2 study is expected to initiate in 2026. Additionally, Seres is exploring label expansion for VOWST into pediatric populations and other C. difficile infection settings. The company also continues to evaluate strategic partnerships to maximize the value of its platform. While Seres faces typical commercial-stage risks and a relatively thin late-stage pipeline, its first-mover advantage in oral microbiome therapeutics and strong IP position support a moderate conviction.

Upcoming Catalysts (preview)

• H2 2026Initiation of Phase 2 trial for SER-155 in allo-HSCT70% success
• 2027VOWST label expansion to pediatric recurrent C. difficile60% success
• TBDNew partnership or licensing deal for platform or pipeline asset50% success